Compare LGN & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGN | APLS |
|---|---|---|
| Founded | 1963 | 2009 |
| Country | United States | United States |
| Employees | 7000 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.2B |
| IPO Year | N/A | 2015 |
| Metric | LGN | APLS |
|---|---|---|
| Price | $82.02 | $41.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 17 | 21 |
| Target Price | ★ $59.50 | $33.59 |
| AVG Volume (30 Days) | 1.5M | ★ 9.9M |
| Earning Date | 05-15-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $53.66 | N/A |
| Revenue Next Year | $11.99 | $18.19 |
| P/E Ratio | ★ N/A | $273.60 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $28.31 | $16.83 |
| 52 Week High | $107.24 | $41.14 |
| Indicator | LGN | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 84.57 |
| Support Level | $77.55 | $19.29 |
| Resistance Level | $107.24 | $41.14 |
| Average True Range (ATR) | 5.84 | 0.06 |
| MACD | -1.83 | -0.65 |
| Stochastic Oscillator | 15.97 | 58.33 |
Legence Corp is a provider of engineering, installation, and maintenance services for critical systems in buildings. It focuses on sectors that have technically demanding buildings, including technology, life sciences, healthcare, and education. Legence specializes in designing, fabricating, and installing complex heating, ventilation, and air conditioning (HVAC), process piping, and other mechanical, electrical, and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting, and building controls in existing facilities to enhance building performance, reliability, and efficiency. The services are mainly provided on a fixed price basis. The company has two reportable segments: Installation and Maintenance, which generates the maximum revenue, and Engineering and Consulting.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).